Nocturnal Labs – Scouting, investing

Scouting, Investing in and Nurturing Healthcare Innovation

Innovative technology platforms based on plant-derived extracellular vesicles for vaccines and wound care therapies

Development of a novel treatment for small abdominal aortic aneurysms

A biopharmaceutical company focused on the next generation of antibody therapeutics

A clinical-stage drug company developing a high-dose statin for early intervention in a blinding eye disease.

Nocturnal Labs is an operational industrial holding that invests in companies developing disruptive healthcare products, services and technologies.

NOCTURNAL LABS TEAM

A cumulative 160+ years of experience in the healthcare industry…

SEE OUR COMPANIES

Young, very agile and highly innovative companies burning up with ideas…

LATEST NEWS

EPOK Therapeutics

EPOK Therapeutics announced today the completion of a $9.0m Seed Round financing

23 March 2023

EPOK Therapeutics Inc. (“EPOK” or the “Company”), a preclinical stage biotech company developing diabodies and antibody conjugates, announced today the completion of a $9.0m Seed Round financing, led by Canadian and Italian angel investors. The proceeds from the financing will support the preclinical development of two proprietary drug candidates. In conjunction with the financing, the […]

dyverto

DYVERTO AG GETS A COMBINED “SEED” FUNDING OF NEARLY 1 MILLION EUROS for the development of a novel treatment for small abdominal aortic aneurysms.

24 August 2022

Dyverto AG, an innovative start-up operating in the vascular sector created by CVLab, announces the entry into the share capital of Davide Bianchi and Nocturnal Labs SpA. The “seed” investment is intended for the development of a device aimed at stopping and potentially reversing the progression of arterial aneurysms. The funds will be used to […]